The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences", writes Giulia Gaudenzi in a column.

Oasmia tar in 151 miljoner – och byter namn

Styrelsen i cancerforskningsföretaget Oasmia har beslutat om en nyemission på 151 miljoner kronor. Samtidigt föreslås ett namnbyte av företaget till Vivesto.

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Synartro rekryterar Eva Arlander

Sveriges Farmaceuters tidigare förbundsdirektör Eva Arlander börjar på Synartro.

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Science Sweden´s Editor-in-Chief, in an editorial.

New diagnostic test soon ready for the market

"Imponerande kraftsamling gav vaccin"

Det rekordsnabba framtagandet av nya vaccin under pandemin visar vad läkemedelsindustrin – och mänskligheten – kan åstadkomma när pressen är tillräckligt stor.

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct site in the gastrontestinal tract are two of them.

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Nascent Invest och Fort Knox investerar i test för bloddoping

Umeåföretaget Pro Test Diagnostics får in 17 miljoner kronor som ska användas för att färdigställa ett test-kit mot bloddoping.

De tar plats på Siemens Healthineers

Rekryterar från Joint Academy och Novartis.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Swedish and Danish Life Science – are there still untapped synergies?

With the increasing developments in life sciences over the past decade and strong support for the sector’s strategic importance from both the Sweden and Danish governments, the timing of The Future of Swedish & Danish Life Science conference could not be better. A one-day conference on ongoing collaborations, new directions and required future investment will held on April 2nd at Medicon Village in Lund.

Upcoming event: New updates on drugs

At Medicon Valley Alliance venues in Copenhagen/Örestad April 1 2020 the meeting New updates in Drug Formulation & Bioavailability takes place for the for the eighth time.

Brexit looking back and looking forward

More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards an exit early 2020.

Engage with your CMO early

Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of Development at Spago Nanomedical says.

Oasmias villkor klara

Två kronor per aktier – så ser villkoren ut för den tidigare aviserade emission på cirka 400 miljoner som läkemedelsutvecklaren Oasmia förbereder. Börskursen faller efter beskedet.